LIMN (Liminatus Pharma) Total Equity: $-0.13 Mil (As of Mar. 2026)


LIMN Liminatus Pharma Inc LIMN
13 GF Score
Price $0.11
! 1 Warning Sign
View Full Analysis

What is Liminatus Pharma Total Equity?

Liminatus Pharma LIMN +1.70% 13 Total Equity is $-0.13 Mil as of Mar. 2026. GuruFocus rates LIMN with a GF Score™ of 13/100. The stock has 1 warning sign investors should review.

Liminatus Pharma's total equity for the quarter that ended in Mar. 2026 was $-0.13 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Liminatus Pharma Total Equity Historical Data

* Premium members only.

The historical data trend for Liminatus Pharma's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Liminatus Pharma Total Equity Chart

Liminatus Pharma Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Total Equity
-10.81 -15.79 -19.34 -9.82

Liminatus Pharma Quarterly Data
Dec22 Mar23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.00 -8.81 -1.65 -9.82 -0.13
LIMN
13GF Score
Liminatus Pharma Inc LIMN
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Liminatus Pharma Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Liminatus Pharma's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=0.513-10.327
=-9.81

Liminatus Pharma's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=2.79-2.923
=-0.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of $-0.13 Mil mean?
Liminatus Pharma (LIMN) has a Total Equity of $-0.13 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Liminatus Pharma and its competitors.
Is Liminatus Pharma's Total Equity too high?
Liminatus Pharma's current Total Equity is $-0.13 Mil. Overall, Liminatus Pharma has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Liminatus Pharma's Total Equity compare to GNPX and PCSA?
Liminatus Pharma's Total Equity of $-0.13 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Liminatus Pharma and its competitors. Liminatus Pharma's current Total Equity is $-0.13 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Liminatus Pharma stock overvalued right now?
Liminatus Pharma (LIMN) has a current Total Equity of $-0.13 Mil. The current Total Equity is $-0.13 Mil. Liminatus Pharma's overall GF Score™ is 13/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Liminatus Pharma (LIMN), the current Total Equity is $-0.13 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Liminatus Pharma Business Description

Address 12611 Hiddencreek Way, Unit C, Cerritos, CA, USA, 90703
Liminatus Pharma Inc is a clinical-stage biopharmaceutical company engaged in developing cancer therapies and treatments. The company is developing a next generation CD47 immune checkpoint inhibitor that enables cancer cells to evade detection by the immune system. Anti-CD47 monoclonal antibodies generally induce anemia and thrombocytopenia due to their binding to red blood cells and platelets. The Liminatus CD47 mAb has shown to preferentially bind to immune cells, but not to red blood cells and platelets and does not induce hemolysis. The clinical candidate is currently in the late preclinical stage.
13GF Score

Get the complete analysis for LIMN

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.11
Price